Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Advertisement Study and Other Alzheimer’s Disease Pipeline Research at The Clinical Trials on Alzheimer’s Disease (CTAD) Conference
TOKYO, Oct 16, 2023 – (JCN Newswire) – Eisai Co. Ltd revealed today that the business will present brand-new information from the stage 3 Clarity ADVERTISEMENT researchstudy for its Alzheimer’s illness (AD) treatment LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous usage and brand-new information on the subcutaneous solution in advancement at the 16th yearly Clinical Trials on Alzheimer’s Disease (CTAD) conference. The conference will be held in Boston, Massachusetts, United States and essentially from October 24 to 27,2023 In addition to the information provided on Eisai’s anti-amyloid beta (Aβ) protofibrilantibody LEQEMBI, stage 1 information for E2511, an investigational tropomyosin receptor Kinase A (TrkA) favorable allosteric modulator (PAM), will be provided as well as other researchstudy from the business’s ADVERTISEMENT pipeline. At the conference, Eisai will present information and researchstudy in 5 oral and 10 poster discussions. BioArctic will provide an oral discussion on lecanemab.
Late-Breaking Symposium 4 – Lecanemab for early Alzheimer’s Disease: Long-Term Outcomes, Predictive Biomarkers, and Novel Subcutaneous Administration